You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameGranisetron
Accession NumberDB00889  (APRD01002)
TypeSmall Molecule
GroupsApproved, Investigational
Description

A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. [PubChem]

Structure
Thumb
Synonyms
granisétron
granisetrón
granisetronum
External Identifiers
  • APF-530
  • APF530
  • BRL 43694
  • BRL-43694
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Granisetron Hydrochloride Injectionsolution1 mgintravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Granisetron Hydrochloride Injectionliquid1 mgintravenousOmega Laboratories Ltd2009-05-14Not applicableCanada
Granisetron Hydrochloride Injectionliquid1 mgintravenousSandoz Canada Incorporated2009-02-20Not applicableCanada
Granisetron Hydrochloride Injection Sdzsolution1 mgintravenousSandoz Canada Incorporated2012-12-19Not applicableCanada
Kytril 1mg/1mlliquid1 mgintravenousHoffmann La Roche Limited1996-12-312012-01-06Canada
Kytril Tablets 1mgtablet1 mgoralHoffmann La Roche Limited1996-12-312015-11-06Canada
Nat-granisetrontablet1 mgoralNatco Pharma (Canada) Inc2016-03-01Not applicableCanada
Sancusopatch3.1 mg/24htransdermalPro Strakan, Inc.2008-09-12Not applicableUs
Sancusopatch3.1 mg/24htransdermalPhysicians Total Care, Inc.2009-02-16Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-granisetrontablet1 mgoralApotex Inc2009-02-20Not applicableCanada
Granisetroninjection, solution1 mg/mLintravenousFresenius Kabi USA, LLC2009-11-20Not applicableUs
Granisetroninjection1 mg/mLintravenousSandoz Inc2008-06-30Not applicableUs
Granisetroninjection1 mg/mLintravenousSandoz Inc2008-06-30Not applicableUs
Granisetroninjection, solution.1 mg/mLintravenousFresenius Kabi USA, LLC2009-11-20Not applicableUs
Granisetroninjection, solution1 mg/mLintravenousFresenius Kabi USA, LLC2009-11-20Not applicableUs
Granisetron Hydrochlorideinjection.1 mg/mLintravenousWockhardt Limited2008-03-03Not applicableUs
Granisetron Hydrochloridetablet1 mg/1oralRoxane Laboratories, Inc2008-05-16Not applicableUs
Granisetron Hydrochlorideinjection.1 mg/mLintravenousAkorn, Inc.2009-10-01Not applicableUs
Granisetron Hydrochloridetablet, film coated1 mg/1oralOrchid Pharma Inc2016-04-12Not applicableUs
Granisetron Hydrochlorideinjection1 mg/mLintravenousWockhardt Limited2008-06-30Not applicableUs
Granisetron Hydrochlorideinjection1 mg/mLintravenousAkorn, Inc.2009-10-01Not applicableUs
Granisetron Hydrochloridetablet, film coated1 mg/1oralAvera Mc Kennan Hospital2015-03-02Not applicableUs
Granisetron Hydrochloridetablet1 mg/1oralBreckenridge Pharmaceutical, Inc.2009-06-22Not applicableUs
Granisetron Hydrochloridetablet, film coated1 mg/1oralCore Pharma, Llc2007-12-312016-03-15Us
Granisetron Hydrochloridetablet, film coated1 mg/1oralNorthstar Rx LLC2008-04-29Not applicableUs
Granisetron Hydrochlorideinjection4 mg/4mLintravenousCipla USA Inc.2008-06-30Not applicableUs
Granisetron Hydrochloridetablet, film coated1 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2010-05-28Not applicableUs
Granisetron Hydrochlorideinjection.1 mg/mLintravenousWOCKHARDT USA LLC2008-03-03Not applicableUs
Granisetron Hydrochlorideinjection1 mg/mLintravenousWest ward Pharmaceutical Corp2009-12-23Not applicableUs
Granisetron Hydrochlorideinjection1 mg/mLintravenousCipla USA Inc.2008-06-30Not applicableUs
Granisetron Hydrochlorideinjection, solution1 mg/mLintravenousSagent Pharmaceuticals2010-12-01Not applicableUs
Granisetron Hydrochlorideinjection1 mg/mLintravenousWOCKHARDT USA LLC2008-06-30Not applicableUs
Granisetron Hydrochlorideinjection1 mg/mLintravenousWest ward Pharmaceutical Corp2009-12-23Not applicableUs
Granisetron Hydrochlorideinjection, solution1 mg/mLintravenousSagent Pharmaceuticals2010-12-01Not applicableUs
Granisetron Hydrochlorideinjection.1 mg/mLintravenousCipla Limited2007-12-31Not applicableUs
Granisetron Hydrochloridetablet, film coated1 mg/1oralTeva Pharmaceuticals USA Inc2008-01-02Not applicableUs
Granisetron Hydrochlorideinjection, solution.1 mg/mLintravenousSagent Pharmaceuticals2010-12-01Not applicableUs
Granisetron Hydrochloridetablet1 mg/1oralAscend Laboratories, LLC2010-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
GranisolNot Available
KevatrilNot Available
KytrilNot Available
SustolNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Granisetron hydrochloride
107007-99-8
Thumb
  • InChI Key: QYZRTBKYBJRGJB-WQTKJZBYSA-N
  • Monoisotopic Mass: 348.1716891
  • Average Mass: 348.88
DBSALT000485
Categories
UNIIWZG3J2MCOL
CAS number109889-09-0
WeightAverage: 312.417
Monoisotopic: 312.195011409
Chemical FormulaC18H24N4O
InChI KeyMFWNKCLOYSRHCJ-BTTYYORXSA-N
InChI
InChI=1S/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12-,13+,14-
IUPAC Name
1-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-1H-indazole-3-carboxamide
SMILES
CN1N=C(C(=O)N[C@@H]2C[C@@H]3CCC[[email protected]](C2)N3C)C2=C1C=CC=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as indazole-3-carboxamides. These are aromatic compounds containing an indazole ring system that is substituted at the 3-position with a carboxamide group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzopyrazoles
Sub ClassIndazoles
Direct ParentIndazole-3-carboxamides
Alternative Parents
Substituents
  • Indazole-3-carboxamide
  • 2-heteroaryl carboxamide
  • Pyrazole-5-carboxamide
  • Piperidine
  • Benzenoid
  • Azole
  • Heteroaromatic compound
  • Pyrazole
  • Amino acid or derivatives
  • Carboxamide group
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxylic acid derivative
  • Azacycle
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Organic oxide
  • Organic oxygen compound
  • Hydrocarbon derivative
  • Organic nitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
PharmacodynamicsGranisetron is a selective inhibitor of type 3 serotonergic (5-HT3) receptors. Granisetron has little or no affinity for other serotonin receptors, including 5-HT 1 , 5-HT 1A , 5-HT 1B/C , or 5-HT 2 ; for alpha 1 -, alpha 2 -, or beta-adrenoreceptors; for dopamine D 2 receptors; for histamine H 1 receptors; for benzodiazepine receptors; for picrotoxin receptors; or for opioid receptors. In most human studies, granisetron has had little effect on blood pressure, heart rate, or electrocardiogram (ECG). The drug is structurally and pharmacologically related to ondansetron, another selective inhibitor of 5-HT3 receptors. The serontonin 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT3 receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting.
Mechanism of actionGranisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
Related Articles
AbsorptionAbsorption of is rapid and complete, though oral bioavailability is reduced to about 60% as a result of first pass metabolism.
Volume of distributionNot Available
Protein binding65%
Metabolism

Primarily hepatic; undergoes N -demethylation and aromatic ring oxidation followed by conjugation. Animal studies suggest that some of the metabolites may have 5-HT 3 receptor antagonist activity.

SubstrateEnzymesProduct
Granisetron
9'-desmethylgranisetronDetails
Granisetron
7-hydroxygranisetronDetails
Route of eliminationThe remainder of the dose is excreted as metabolites, 48% in the urine and 38% in the feces.
Half life4-6 hours in healthy patients, 9-12 hours in cancer patients
Clearance
  • 0.52 L/h/kg [Cancer Patients with 1 mg bid for 7 days]
  • 0.41 L/h/kg [Healthy subject with a single 1 mg dose]
ToxicityLD50>2000 mg/kg (rat, oral)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9947
Blood Brain Barrier+0.9515
Caco-2 permeable+0.5231
P-glycoprotein substrateSubstrate0.5473
P-glycoprotein inhibitor IInhibitor0.6287
P-glycoprotein inhibitor IIInhibitor0.7243
Renal organic cation transporterNon-inhibitor0.5895
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6978
CYP450 1A2 substrateNon-inhibitor0.8546
CYP450 2C9 inhibitorNon-inhibitor0.9019
CYP450 2D6 inhibitorNon-inhibitor0.8841
CYP450 2C19 inhibitorNon-inhibitor0.9073
CYP450 3A4 inhibitorNon-inhibitor0.8355
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6016
Ames testNon AMES toxic0.5878
CarcinogenicityNon-carcinogens0.8464
BiodegradationNot ready biodegradable0.9868
Rat acute toxicity2.3943 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9083
hERG inhibition (predictor II)Inhibitor0.5458
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Strakan international ltd
  • Akorn inc
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories
  • Claris lifesciences ltd
  • Dr reddys laboratories inc
  • Ebewe pharma
  • Sagent strides llc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Wockhardt usa inc
  • App pharmaceuticals
  • Hikma farmaceutica (portugal) sa
  • Hoffmann la roche inc
  • Cypress pharmaceutical inc
  • Apotex inc
  • Barr laboratories inc
  • Cipla ltd
  • Corepharma llc
  • Dr reddys laboratories ltd
  • Mylan pharmaceuticals inc
  • Natco pharma ltd
  • Orchid healthcare
  • Roxane laboratories inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa
Packagers
Dosage forms
FormRouteStrength
Injectionintravenous.1 mg/mL
Injectionintravenous1 mg/mL
Injectionintravenous4 mg/4mL
Injection, solutionintravenous.1 mg/mL
Injection, solutionintravenous1 mg/mL
Tabletoral1 mg/1
Tablet, film coatedoral1 mg/1
Liquidintravenous1 mg
Solutionintravenous1 mg
Tabletoral1 mg
Patchtransdermal3.1 mg/24h
Prices
Unit descriptionCostUnit
Sancuso 3.1 mg/24 hr patch372.0USD patch
Kytril 2 1 mg tablet Box131.98USD box
Kytril 1 mg tablet62.94USD tablet
Granisetron hcl 1 mg tablet60.19USD tablet
Granisetron hcl 4 mg/4 ml vial24.0USD ml
Kytril 1 mg Tablet20.27USD tablet
Apo-Granisetron 1 mg Tablet14.14USD tablet
Kytril 0.1 mg/ml vial11.54USD ml
Granisetron hcl 0.1 mg/ml vial7.2USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2100777 No2003-08-192012-01-16Canada
CA2158354 No2004-07-132014-03-15Canada
US5952340 No1996-09-142016-09-14Us
US7608282 No2004-10-222024-10-22Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point219 °C (HCl salt)Not Available
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.434 mg/mLALOGPS
logP2.64ALOGPS
logP1.88ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)14.75ChemAxon
pKa (Strongest Basic)9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area50.16 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity101.83 m3·mol-1ChemAxon
Polarizability35.57 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Neal Ward, David Alan Jones, Victor Witold Jacewicz, “Process for the preparation of granisetron.” U.S. Patent US6268498, issued April, 1986.

US6268498
General References
  1. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. [PubMed:15740177 ]
  2. Tan M: Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71. [PubMed:12943486 ]
  3. Feyer P, Seegenschmiedt MH, Steingraeber M: Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies. Support Care Cancer. 2005 Sep;13(9):671-8. Epub 2005 Jul 26. [PubMed:16044252 ]
External Links
ATC CodesA04AA02
AHFS Codes
  • 56:22.20
PDB EntriesNot Available
FDA labelDownload (77.3 KB)
MSDSDownload (51.7 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe metabolism of Granisetron can be decreased when combined with Abiraterone.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Granisetron.
AlmotriptanGranisetron may increase the serotonergic activities of Almotriptan.
AmantadineAmantadine may increase the QTc-prolonging activities of Granisetron.
AmiodaroneGranisetron may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Granisetron can be decreased when combined with Amiodarone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Granisetron.
AmitriptylineGranisetron may increase the serotonergic activities of Amitriptyline.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Granisetron.
AmoxapineGranisetron may increase the serotonergic activities of Amoxapine.
AnagrelideGranisetron may increase the QTc-prolonging activities of Anagrelide.
ApomorphineGranisetron may increase the hypotensive activities of Apomorphine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Granisetron.
AprepitantThe serum concentration of Granisetron can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Granisetron.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Granisetron.
Arsenic trioxideGranisetron may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherGranisetron may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Granisetron can be decreased when combined with Artemether.
AsenapineGranisetron may increase the QTc-prolonging activities of Asenapine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Granisetron.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Granisetron.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Granisetron.
BedaquilineGranisetron may increase the QTc-prolonging activities of Bedaquiline.
BetaxololThe metabolism of Granisetron can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Granisetron can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Granisetron can be decreased when combined with Boceprevir.
BortezomibBortezomib may increase the QTc-prolonging activities of Granisetron.
BosentanThe serum concentration of Granisetron can be decreased when it is combined with Bosentan.
BromocriptineGranisetron may increase the serotonergic activities of Bromocriptine.
BupropionThe metabolism of Granisetron can be decreased when combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Granisetron.
BuspironeGranisetron may increase the serotonergic activities of Buspirone.
CabergolineGranisetron may increase the serotonergic activities of Cabergoline.
CarbamazepineThe metabolism of Granisetron can be increased when combined with Carbamazepine.
CelecoxibThe metabolism of Granisetron can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Granisetron can be increased when it is combined with Ceritinib.
CeritinibGranisetron may increase the QTc-prolonging activities of Ceritinib.
ChloroquineGranisetron may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Granisetron can be decreased when combined with Chloroquine.
ChlorpromazineGranisetron may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe metabolism of Granisetron can be decreased when combined with Chlorpromazine.
CholecalciferolThe metabolism of Granisetron can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Granisetron can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Granisetron can be decreased when combined with Cinacalcet.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Granisetron.
CisaprideGranisetron may increase the QTc-prolonging activities of Cisapride.
CitalopramGranisetron may increase the QTc-prolonging activities of Citalopram.
CitalopramThe metabolism of Granisetron can be decreased when combined with Citalopram.
ClarithromycinGranisetron may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Granisetron can be decreased when combined with Clemastine.
ClobazamThe metabolism of Granisetron can be decreased when combined with Clobazam.
ClomipramineClomipramine may increase the QTc-prolonging activities of Granisetron.
ClomipramineGranisetron may increase the serotonergic activities of Clomipramine.
ClotrimazoleThe metabolism of Granisetron can be decreased when combined with Clotrimazole.
ClozapineGranisetron may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Granisetron can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Granisetron can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Granisetron can be decreased when combined with Cocaine.
ConivaptanThe serum concentration of Granisetron can be increased when it is combined with Conivaptan.
CrizotinibGranisetron may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Granisetron can be decreased when combined with Crizotinib.
CyclobenzaprineGranisetron may increase the serotonergic activities of Cyclobenzaprine.
CyclosporineThe metabolism of Granisetron can be decreased when combined with Cyclosporine.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Granisetron.
DarifenacinThe metabolism of Granisetron can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Granisetron can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Granisetron can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Granisetron can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Granisetron.
DelavirdineThe metabolism of Granisetron can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Granisetron.
DesipramineDesipramine may increase the QTc-prolonging activities of Granisetron.
DesipramineGranisetron may increase the serotonergic activities of Desipramine.
DesvenlafaxineGranisetron may increase the serotonergic activities of Desvenlafaxine.
DexamethasoneThe serum concentration of Granisetron can be decreased when it is combined with Dexamethasone.
DextromethorphanGranisetron may increase the serotonergic activities of Dextromethorphan.
DihydroergotamineThe metabolism of Granisetron can be decreased when combined with Dihydroergotamine.
DihydroergotamineGranisetron may increase the serotonergic activities of Dihydroergotamine.
DiltiazemThe metabolism of Granisetron can be decreased when combined with Diltiazem.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Granisetron.
DisopyramideGranisetron may increase the QTc-prolonging activities of Disopyramide.
DofetilideGranisetron may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Granisetron.
DomperidoneGranisetron may increase the QTc-prolonging activities of Domperidone.
DoxepinDoxepin may increase the QTc-prolonging activities of Granisetron.
DoxepinGranisetron may increase the serotonergic activities of Doxepin.
DoxycyclineThe metabolism of Granisetron can be decreased when combined with Doxycycline.
DronedaroneGranisetron may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Granisetron can be decreased when combined with Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Granisetron.
DuloxetineGranisetron may increase the serotonergic activities of Duloxetine.
DuloxetineThe metabolism of Granisetron can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Granisetron can be decreased when it is combined with Efavirenz.
EletriptanGranisetron may increase the serotonergic activities of Eletriptan.
EliglustatGranisetron may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Granisetron can be decreased when combined with Eliglustat.
EnzalutamideThe serum concentration of Granisetron can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateGranisetron may increase the serotonergic activities of Ergoloid mesylate.
ErgonovineGranisetron may increase the serotonergic activities of Ergonovine.
ErgotamineGranisetron may increase the serotonergic activities of Ergotamine.
EribulinEribulin may increase the QTc-prolonging activities of Granisetron.
ErythromycinGranisetron may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Granisetron can be decreased when combined with Erythromycin.
EscitalopramGranisetron may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Granisetron can be decreased when it is combined with Eslicarbazepine acetate.
EtravirineThe serum concentration of Granisetron can be decreased when it is combined with Etravirine.
EzogabineEzogabine may increase the QTc-prolonging activities of Granisetron.
FamotidineFamotidine may increase the QTc-prolonging activities of Granisetron.
FelbamateFelbamate may increase the QTc-prolonging activities of Granisetron.
FentanylGranisetron may increase the serotonergic activities of Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Granisetron.
FingolimodFingolimod may increase the QTc-prolonging activities of Granisetron.
FlecainideGranisetron may increase the QTc-prolonging activities of Flecainide.
FluconazoleFluconazole may increase the QTc-prolonging activities of Granisetron.
FluoxetineGranisetron may increase the QTc-prolonging activities of Fluoxetine.
FluoxetineThe metabolism of Granisetron can be decreased when combined with Fluoxetine.
FlupentixolGranisetron may increase the QTc-prolonging activities of Flupentixol.
FluvoxamineThe metabolism of Granisetron can be decreased when combined with Fluvoxamine.
FluvoxamineGranisetron may increase the serotonergic activities of Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Granisetron.
FosamprenavirThe metabolism of Granisetron can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Granisetron can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Granisetron.
FosphenytoinThe metabolism of Granisetron can be increased when combined with Fosphenytoin.
FrovatriptanGranisetron may increase the serotonergic activities of Frovatriptan.
Fusidic AcidThe serum concentration of Granisetron can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Granisetron.
GalantamineGalantamine may increase the QTc-prolonging activities of Granisetron.
GemifloxacinGranisetron may increase the QTc-prolonging activities of Gemifloxacin.
GoserelinGoserelin may increase the QTc-prolonging activities of Granisetron.
HaloperidolGranisetron may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe metabolism of Granisetron can be decreased when combined with Haloperidol.
HistrelinHistrelin may increase the QTc-prolonging activities of Granisetron.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Granisetron.
IbandronateIbandronate may increase the QTc-prolonging activities of Granisetron.
IbutilideGranisetron may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Granisetron can be increased when it is combined with Idelalisib.
IloperidoneGranisetron may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe metabolism of Granisetron can be decreased when combined with Imatinib.
ImipramineImipramine may increase the QTc-prolonging activities of Granisetron.
ImipramineGranisetron may increase the serotonergic activities of Imipramine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Granisetron.
IndapamideIndapamide may increase the QTc-prolonging activities of Granisetron.
IndinavirThe metabolism of Granisetron can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Granisetron can be decreased when combined with Isavuconazonium.
IsocarboxazidGranisetron may increase the serotonergic activities of Isocarboxazid.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Granisetron.
IsoniazidThe metabolism of Granisetron can be decreased when combined with Isoniazid.
IsradipineIsradipine may increase the QTc-prolonging activities of Granisetron.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Granisetron.
IvabradineIvabradine may increase the QTc-prolonging activities of Granisetron.
IvacaftorThe serum concentration of Granisetron can be increased when it is combined with Ivacaftor.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Granisetron.
LapatinibLapatinib may increase the QTc-prolonging activities of Granisetron.
LenvatinibGranisetron may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Granisetron.
LevofloxacinGranisetron may increase the QTc-prolonging activities of Levofloxacin.
LevomilnacipranGranisetron may increase the serotonergic activities of Levomilnacipran.
LinezolidGranisetron may increase the serotonergic activities of Linezolid.
LithiumLithium may increase the QTc-prolonging activities of Granisetron.
LithiumGranisetron may increase the serotonergic activities of Lithium.
LopinavirGranisetron may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Granisetron can be decreased when combined with Lopinavir.
LorcaserinGranisetron may increase the serotonergic activities of Lorcaserin.
LorcaserinThe metabolism of Granisetron can be decreased when combined with Lorcaserin.
LovastatinThe metabolism of Granisetron can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Granisetron can be increased when it is combined with Luliconazole.
LumefantrineGranisetron may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Granisetron can be decreased when combined with Lumefantrine.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Granisetron.
MaprotilineGranisetron may increase the serotonergic activities of Maprotiline.
MefloquineMefloquine may increase the QTc-prolonging activities of Granisetron.
MethadoneGranisetron may increase the serotonergic activities of Methadone.
MethadoneThe metabolism of Granisetron can be decreased when combined with Methadone.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Granisetron.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Granisetron.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Granisetron.
MetoprololThe metabolism of Granisetron can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Granisetron.
MifepristoneMifepristone may increase the QTc-prolonging activities of Granisetron.
MilnacipranGranisetron may increase the serotonergic activities of Milnacipran.
MirabegronMirabegron may increase the QTc-prolonging activities of Granisetron.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Granisetron.
MirtazapineGranisetron may increase the serotonergic activities of Mirtazapine.
MitotaneThe serum concentration of Granisetron can be decreased when it is combined with Mitotane.
MoclobemideGranisetron may increase the serotonergic activities of Moclobemide.
ModafinilThe serum concentration of Granisetron can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Granisetron.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Granisetron.
NafcillinThe serum concentration of Granisetron can be decreased when it is combined with Nafcillin.
NaratriptanGranisetron may increase the serotonergic activities of Naratriptan.
NefazodoneThe metabolism of Granisetron can be decreased when combined with Nefazodone.
NefazodoneGranisetron may increase the serotonergic activities of Nefazodone.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Granisetron.
NetupitantThe serum concentration of Granisetron can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Granisetron can be decreased when combined with Nevirapine.
NicardipineNicardipine may increase the QTc-prolonging activities of Granisetron.
NilotinibGranisetron may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Granisetron can be decreased when combined with Nilotinib.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Granisetron.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Granisetron.
NortriptylineGranisetron may increase the serotonergic activities of Nortriptyline.
OctreotideOctreotide may increase the QTc-prolonging activities of Granisetron.
OfloxacinGranisetron may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Granisetron.
OlaparibThe metabolism of Granisetron can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Granisetron.
OndansetronGranisetron may increase the QTc-prolonging activities of Ondansetron.
OsimertinibThe serum concentration of Granisetron can be increased when it is combined with Osimertinib.
OxytocinOxytocin may increase the QTc-prolonging activities of Granisetron.
PalbociclibThe serum concentration of Granisetron can be increased when it is combined with Palbociclib.
PaliperidoneGranisetron may increase the QTc-prolonging activities of Paliperidone.
PanobinostatGranisetron may increase the arrhythmogenic activities of Panobinostat.
PanobinostatThe metabolism of Granisetron can be decreased when combined with Panobinostat.
ParoxetineParoxetine may increase the QTc-prolonging activities of Granisetron.
ParoxetineGranisetron may increase the serotonergic activities of Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Granisetron.
PazopanibGranisetron may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Granisetron can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Granisetron.
PentobarbitalThe metabolism of Granisetron can be increased when combined with Pentobarbital.
PerflutrenPerflutren may increase the QTc-prolonging activities of Granisetron.
PethidineGranisetron may increase the serotonergic activities of Pethidine.
PhenelzineGranisetron may increase the serotonergic activities of Phenelzine.
PhenobarbitalThe metabolism of Granisetron can be increased when combined with Phenobarbital.
PhenytoinThe metabolism of Granisetron can be increased when combined with Phenytoin.
PimozideGranisetron may increase the QTc-prolonging activities of Pimozide.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Granisetron.
PrimaquineGranisetron may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe metabolism of Granisetron can be increased when combined with Primidone.
ProcainamideGranisetron may increase the QTc-prolonging activities of Procainamide.
ProcarbazineGranisetron may increase the serotonergic activities of Procarbazine.
PromazineGranisetron may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Granisetron can be decreased when combined with Promazine.
PromethazinePromethazine may increase the QTc-prolonging activities of Granisetron.
PromethazineGranisetron may increase the serotonergic activities of Promethazine.
PropafenoneGranisetron may increase the QTc-prolonging activities of Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Granisetron.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Granisetron.
ProtriptylineGranisetron may increase the serotonergic activities of Protriptyline.
QuetiapineGranisetron may increase the QTc-prolonging activities of Quetiapine.
QuinidineGranisetron may increase the QTc-prolonging activities of Quinidine.
QuinidineThe metabolism of Granisetron can be decreased when combined with Quinidine.
QuinineGranisetron may increase the QTc-prolonging activities of Quinine.
QuinineThe metabolism of Granisetron can be decreased when combined with Quinine.
RanolazineRanolazine may increase the QTc-prolonging activities of Granisetron.
RasagilineGranisetron may increase the serotonergic activities of Rasagiline.
RifabutinThe metabolism of Granisetron can be increased when combined with Rifabutin.
RifampicinThe metabolism of Granisetron can be increased when combined with Rifampicin.
RifapentineThe metabolism of Granisetron can be increased when combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Granisetron.
RisperidoneRisperidone may increase the QTc-prolonging activities of Granisetron.
RitonavirRitonavir may increase the QTc-prolonging activities of Granisetron.
RizatriptanGranisetron may increase the serotonergic activities of Rizatriptan.
RolapitantThe metabolism of Granisetron can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Granisetron can be decreased when combined with Ropinirole.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Granisetron.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Granisetron.
SaquinavirGranisetron may increase the QTc-prolonging activities of Saquinavir.
SelegilineGranisetron may increase the serotonergic activities of Selegiline.
SertralineSertraline may increase the QTc-prolonging activities of Granisetron.
SertralineGranisetron may increase the serotonergic activities of Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Granisetron.
SildenafilThe metabolism of Granisetron can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Granisetron can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Granisetron can be increased when it is combined with Simeprevir.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Granisetron.
SorafenibSorafenib may increase the QTc-prolonging activities of Granisetron.
SotalolGranisetron may increase the QTc-prolonging activities of Sotalol.
St. John's WortThe serum concentration of Granisetron can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Granisetron can be increased when it is combined with Stiripentol.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Granisetron.
SulfisoxazoleGranisetron may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Granisetron can be decreased when combined with Sulfisoxazole.
SumatriptanGranisetron may increase the serotonergic activities of Sumatriptan.
SunitinibSunitinib may increase the QTc-prolonging activities of Granisetron.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Granisetron.
TapentadolGranisetron may decrease the analgesic activities of Tapentadol.
Tedizolid PhosphateGranisetron may increase the serotonergic activities of Tedizolid Phosphate.
TelaprevirThe metabolism of Granisetron can be decreased when combined with Telaprevir.
TelavancinGranisetron may increase the QTc-prolonging activities of Telavancin.
TelithromycinGranisetron may increase the QTc-prolonging activities of Telithromycin.
TerbinafineThe metabolism of Granisetron can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Granisetron.
TetrabenazineGranisetron may increase the QTc-prolonging activities of Tetrabenazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Granisetron.
ThioridazineThe metabolism of Granisetron can be decreased when combined with Thioridazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Granisetron.
TiclopidineThe metabolism of Granisetron can be decreased when combined with Ticlopidine.
TipranavirThe metabolism of Granisetron can be decreased when combined with Tipranavir.
TizanidineTizanidine may increase the QTc-prolonging activities of Granisetron.
TocilizumabThe serum concentration of Granisetron can be decreased when it is combined with Tocilizumab.
TolterodineTolterodine may increase the QTc-prolonging activities of Granisetron.
ToremifeneGranisetron may increase the QTc-prolonging activities of Toremifene.
TramadolGranisetron may decrease the analgesic activities of Tramadol.
TranylcypromineGranisetron may increase the serotonergic activities of Tranylcypromine.
TranylcypromineThe metabolism of Granisetron can be decreased when combined with Tranylcypromine.
TrazodoneTrazodone may increase the QTc-prolonging activities of Granisetron.
TrazodoneGranisetron may increase the serotonergic activities of Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Granisetron.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Granisetron.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Granisetron.
TrimipramineGranisetron may increase the serotonergic activities of Trimipramine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Granisetron.
VandetanibGranisetron may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Granisetron.
VemurafenibGranisetron may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Granisetron.
VenlafaxineGranisetron may increase the serotonergic activities of Venlafaxine.
VerapamilThe metabolism of Granisetron can be decreased when combined with Verapamil.
VilanterolVilanterol may increase the QTc-prolonging activities of Granisetron.
VilazodoneGranisetron may increase the serotonergic activities of Vilazodone.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Granisetron.
VorinostatVorinostat may increase the QTc-prolonging activities of Granisetron.
VortioxetineGranisetron may increase the serotonergic activities of Vortioxetine.
ZiprasidoneGranisetron may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Granisetron can be decreased when combined with Ziprasidone.
ZolmitriptanGranisetron may increase the serotonergic activities of Zolmitriptan.
ZuclopenthixolGranisetron may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Hillsley K, Grundy D: Plasticity in the mesenteric afferent response to cisplatin following vagotomy in the rat. J Auton Nerv Syst. 1999 May 28;76(2-3):93-8. [PubMed:10412832 ]
  2. Turvill JL, Connor P, Farthing MJ: The inhibition of cholera toxin-induced 5-HT release by the 5-HT(3) receptor antagonist, granisetron, in the rat. Br J Pharmacol. 2000 Jul;130(5):1031-6. [PubMed:10882387 ]
  3. Cappelli A, Anzini M, Vomero S, Mennuni L, Makovec F, Doucet E, Hamon M, Menziani MC, De Benedetti PG, Giorgi G, Ghelardini C, Collina S: Novel potent 5-HT(3) receptor ligands based on the pyrrolidone structure: synthesis, biological evaluation, and computational rationalization of the ligand-receptor interaction modalities. Bioorg Med Chem. 2002 Mar;10(3):779-801. [PubMed:11814868 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. [PubMed:15740177 ]
  6. Tan M: Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71. [PubMed:12943486 ]
  7. Ho KY, Gan TJ: Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol. 2006 Dec;19(6):606-11. [PubMed:17093363 ]
  8. Abdelsayed GG: Management of radiation-induced nausea and vomiting. Exp Hematol. 2007 Apr;35(4 Suppl 1):34-6. [PubMed:17379085 ]
  9. Feyer P, Seegenschmiedt MH, Steingraeber M: Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies. Support Care Cancer. 2005 Sep;13(9):671-8. Epub 2005 Jul 26. [PubMed:16044252 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Tan M: Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71. [PubMed:12943486 ]
  2. Janicki PK: Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8. Epub 2005 Sep 26. [PubMed:16192915 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Nakamura H, Ariyoshi N, Okada K, Nakasa H, Nakazawa K, Kitada M: CYP1A1 is a major enzyme responsible for the metabolism of granisetron in human liver microsomes. Curr Drug Metab. 2005 Oct;6(5):469-80. [PubMed:16248838 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 31, 2016 02:13